T

TransMedics

Ex-vivo organ perfusion platform

Head of OCS Kidney Program

Full-TimePosted on 10/16/2026
$408.1k - $509.1k+ Bonus + Equity
Expert
MD
Andover, MA, USA
HybridRegular presence in the Clinical Command Center is required; travel to transplant centers, OPOs, and industry meetings. Headquarters is planned to relocate to Somerville, Massachusetts, by 2028.
Medical, Clinical & VeterinaryPhysicians & Surgeons

About the job

Requirements
  • An MD with advanced surgical training in abdominal organ transplantation is required.
  • At least 7 years of independent surgical experience, including abdominal organ procurement, is required.
  • The candidate must uphold high moral and ethical standards.
  • The candidate must have a proven ability to build, manage, and develop teams while fostering engagement and accountability.
  • The candidate must have customer-facing skills and the ability to engage effectively with clinical staff at sites and advocate for the OCS platform.
  • The candidate must be able to lead teams calmly and decisively, providing clear direction in time-sensitive, mission-critical environments.
  • The candidate must communicate effectively with internal teams and clinical sites at all organizational levels.
  • The candidate must be detail-oriented, highly organized, and self-starting.
  • The candidate must collaborate effectively across functions and organizational levels.
  • The candidate must have a proven track record of managing complex clinical and/or commercial programs and projects.
  • The candidate must be able to perform in a fast-paced, dynamic environment under the time and stress constraints of donor surgery and organ transplantation.
  • The role requires 24/7 accountability, participation in the executive on-call escalation rotation, and availability during active critical cases.
  • Regular presence in the Clinical Command Center and travel to transplant centers, OPOs, and industry meetings are required; occasional observation of procedures in clinical settings is also required.
  • The candidate must maintain surgical availability to meet mission demand.
Responsibilities
  • Own all clinical input into product development, design validation, and regulatory readiness for the OCS Kidney program.
  • Optimize the OCS Kidney clinical-use workflow to maximize clinical value and adoption.
  • Develop and refine the OCS Kidney use model from research and development through clinical application, aligning it with product design, workflow requirements, and clinical practice.
  • Design and execute preclinical studies required by U.S. and international regulatory bodies to enable initiation of the first-in-human clinical trial.
  • Develop clinical trial protocols and statistical analysis plans in partnership with Clinical Affairs and Regulatory leadership.
  • Develop and execute surgical and clinical training requirements and protocols for internal and external users of the OCS Kidney System.
  • Define clinical requirements for OCS Kidney digital control, remote monitoring, and user experience within the OCS NOP Connect digital ecosystem, in partnership with the Digital Development team.
  • Define clinical requirements for future OCS Kidney product improvements and redesigns based on clinical customer feedback and usability findings.
  • Partner in selecting initial global clinical trial centers.
  • Lead clinical outreach to promote the program in collaboration with the Commercial and Clinical Affairs teams.
  • Own engagement and relationships with surgical leaders at all U.S. trial centers.
  • Represent the program clinically before the CEC and DSMB for all OCS Kidney trials.
  • Meet enrollment targets and ensure timely collection and cleaning of trial data to support on-time regulatory submissions with Clinical Affairs.
  • Own clinical communications to trial sites regarding trial progress.
  • Own clinical data presentations to U.S. and international regulatory bodies and clinical users for the OCS Kidney program.
  • Lead clinical data interpretation and positioning for final clinical study reports of the OCS Kidney trials.
  • Build and maintain relationships with OCS Kidney System users globally, including individual clinicians, hospital systems, and OPOs.
  • Lead planning and execution of user and investigator meetings for the OCS Kidney program.
  • Partner with the Commercial team to introduce the OCS Kidney System to clinical programs globally.
  • Monitor and report OCS Kidney System utilization, device-related issues, user feedback, and other clinically relevant information to key stakeholders on a defined cadence.
  • Lead clinical assessment of field and user complaints through resolution in partnership with the Quality team.
  • Develop and own clinical content for OCS Kidney System customer communications, including PIBs, Clinical Use Models, and field notifications.
  • Support scientific presentations and draft clinical abstracts and publications for OCS Kidney users.
  • Participate in strategic leadership meetings focused on the OCS Kidney program.
  • Perform liver and kidney donor procurement missions in the Northeast region or elsewhere as needed.
  • Perform other duties as assigned.
  • Deliver results in a timely manner and execute corporate goals.
  • Build a high-performing team and a strong talent bench accountable for day-to-day execution of critical program tasks.
  • Maintain a calm, composed demeanor under pressure.
  • Provide high-quality surgical service and maintain surgical availability to meet mission demand.
  • Maintain zero tolerance for ethical, moral, or interpersonal misconduct with peers.

About the company

TransMedics makes the Organ Care System (OCS), a portable platform that keeps donor organs alive outside the body by warm, oxygenated perfusion and continuous viability monitoring. The OCS circulates warmed, nutrient-rich blood through the organ, allowing surgeons to assess health in near-physiological conditions. Revenue comes from selling OCS consoles, disposable sets used per procedure, and the National OCS Program, which provides end-to-end organ retrieval and logistics services. It distinguishes itself by holding FDA approvals to preserve and assess hearts, lungs, and livers in the United States and by integrating hardware, consumables, and logistics to expand transplant opportunities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Andover, Massachusetts

Founded

1998

Get referred to TransMedics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 21% to $189.9 million, and guidance increased to $737-$757 million.
  • FDA approved ENHANCE Heart and DENOVO Lung IDEs in January-February 2026, advancing next-generation trials.
  • PAD Aviation closed July 6, 2026, opening pan-European transplant logistics contracts.

What critics are saying

  • Judge Sorokin partially denied dismissal July 21, 2026, forcing discovery in the fraud case.
  • CHOPS and kidney development burn cash while gross margin slipped to 60% in Q2 2026.
  • A bad ENHANCE or DENOVO safety signal in 2026-2027 would damage OCS credibility.

What makes TransMedics unique

  • FDA-approved OCS remains the only U.S. warm-perfusion platform for hearts, lungs, and livers.
  • The National OCS Program bundles surgeons, logistics, aircraft, and disposables into a sticky ecosystem.
  • PAD Aviation extends TransMedics' logistics moat into Europe, copying the U.S. NOP playbook.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Short Term Disability
  • Long Term Disability
  • Health Savings Account/Flexible Spending Account
  • Dependent Care Flexible Spending Account
  • 401(k) Plan
  • Pet insurance
  • Employee Stock Purchase Plan
  • Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

2%
Yahoo Finance
Oct 1st, 2026
TransMedics director buys $109K in stock amid 30% yearly decline

David Weill, a director at TransMedics Group, purchased 1,336 shares of common stock for approximately $109,000 on 11 September 2026, according to an SEC Form 4 filing. The purchase increased his direct holdings by 9% to 16,392 shares, valued at roughly $1.4 million. The transaction occurred as the stock recorded a one-year return of -30%. TransMedics, a commercial-stage medical technology company with a market capitalisation of $2.7 billion, develops the Organ Care System, a portable device that preserves and monitors donor organs for transplantation. The company reported trailing twelve-month revenues of $668.5 million and net income of $151.7 million. Management has guided for 22%-25% sales growth in 2026 as it expands internationally and develops new platforms.

Yahoo Finance
Sep 15th, 2026
TransMedics and SoFi stocks fall 28% and 34% but show strong buying potential

TransMedics Group and SoFi Technologies have declined 28% and 34% respectively over the past year, presenting potential buying opportunities despite broader market strength driven by tech giants. TransMedics, which developed the Organ Care System for transplants, faces near-term headwinds. Second-quarter revenue grew 21% year over year to $189.9 million, marking a slowdown from recent quarters. Adjusted earnings per share fell 52% to $0.44. However, the company is investing in expansion initiatives, including potential kidney transplant approval and a logistics network for greater control over the organ transplant cycle. These investments are pressuring current profits but could drive future growth. The OCS technology maintains organ temperature and blood supply during transport, addressing limitations of traditional cold storage methods. With a large addressable market remaining, the stock may offer value at current levels.

PR Newswire
Aug 4th, 2026
TransMedics reports 21% revenue growth to $190M in Q2 2026, raises guidance despite margin pressure

TransMedics Group reported second quarter 2026 revenue of $189.9 million, a 21% increase from $157.4 million in the prior year period. The growth was driven primarily by increased utilisation of the company's Organ Care System, particularly in liver and heart transplants through its National OCS Programme, as well as logistics services revenue. Gross margin decreased to 60% from 61% year-over-year, reflecting a higher mix of service revenue and temporary product-cost factors. Net income fell to $14.7 million, or $0.41 per diluted share, compared to $34.9 million, or $0.92 per share, in the second quarter of 2025. The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth. TransMedics develops portable extracorporeal warm perfusion technology for donor organ transplantation.

MarketScreener
Jul 6th, 2026
TransMedics invests in PAD Aviation to build Europe-wide organ transplant air logistics network

TransMedics Group has completed a strategic investment in PAD Aviation service GmbH, a Germany-based private aviation operator. The deal aims to establish a dedicated organ transplantation air logistics network across Europe, replicating TransMedics' OCS NOP model from the US. PAD Aviation, founded in 2006, operates from a 24/7 hub in Paderborn, Germany. The company maintains a fleet of nine Embraer Phenom 300 aircraft and employs over 40 pilots, holding a valid EASA Air Operator Certificate. TransMedics develops portable extracorporeal warm perfusion technology for preserving and assessing donor organs. The investment supports the company's efforts to expand adoption of its OCS perfusion technology and create a pan-European organ transport logistics network across the European Union.

Yahoo Finance
Jul 2nd, 2026
TD Cowen sets $120 target on TransMedics, sees 77% upside on transplant growth

TransMedics Group has received a 'Buy' rating from TD Cowen with a $120 price target, implying 77% upside from its last close. The firm cited growing US transplant activity in heart, liver and lung procedures as a key driver for the company's Organ Care System technology and logistics business. Monthly US transplant data showed volumes rose approximately 5% year-over-year in the second quarter of 2026. TransMedics generated $173.9 million in total revenue in the first quarter of 2026, up 21% year-over-year, with product revenue reaching $108 million and service revenue contributing $66 million. The company ended the quarter with $461.7 million in cash and cash equivalents. Shares closed up 2% on Wednesday and gained further in after-hours trading.